XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Revenue $ 24,109 $ 25,813
Cost of revenue 19,038 19,186
Gross profit 5,071 6,627
Operating expenses:    
Research and development 2,596 1,906
Selling 1,632 1,216
General and administrative 5,451 5,328
Loss on disposition of Tantaline 162
Impairment charge 111
Total operating expenses 9,952 8,450
Operating loss (4,881) [1] (1,823)
Other income (expense):    
Interest income 577 162
Interest expenses (23) (8)
Employee retention credits 1,529
Foreign exchange income (loss) 42 (95)
Other income 91 15
Total other income, net 687 1,603
Loss before income tax (4,194) [1] (220) [2]
Income tax (benefit) expense (14) 4
Net loss $ (4,180) $ (224)
Loss per common share:    
Basic $ (0.62) $ (0.03)
Diluted $ (0.62) $ (0.03)
Weighted average number of shares:    
Basic 6,788 6,734
Diluted 6,788 6,734
[1] CVD Materials segment includes loss on sale of Tantaline of $0.2 million and an impairment charge related to MesoScribe fixed assets of $0.1 million.
[2] Includes other income related to ERCs of $1,103, $303 and $123 for the CVD, SDC and Materials segments, respectively.